Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE003 (CAN) (Dr. Okafor)
· consented 2023-08-23
Adverse events
5
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
mild
assessed
2026-08-18
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-12-30 (study day 118); relationship: Y
mild
assessed
2026-08-18
Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2024-02-06 (study day 156); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Alopecia — outcome: UNKNOWN; onset 2024-03-02 (study day 181); relationship: N
mild
assessed
2026-08-18
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-07-12 (study day 313); relationship: Y
mild
assessed
2026-08-18
Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2024-09-06 (study day 369); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.